- Home
- RNTX vs KORE Comparison
RNTX vs KORE Comparison
Compare RNTX & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- KORE
- Stock Information
- Founded
- RNTX 2001
- KORE 2003
- Country
- RNTX United States
- KORE United States
- Employees
- RNTX N/A
- KORE N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- KORE Telecommunications Equipment
- Sector
- RNTX Health Care
- KORE Consumer Discretionary
- Exchange
- RNTX Nasdaq
- KORE Nasdaq
- Market Cap
- RNTX 40.3M
- KORE 45.0M
- IPO Year
- RNTX N/A
- KORE N/A
- Fundamental
- Price
- RNTX $1.56
- KORE $2.30
- Analyst Decision
- RNTX
- KORE Hold
- Analyst Count
- RNTX 0
- KORE 2
- Target Price
- RNTX N/A
- KORE $2.75
- AVG Volume (30 Days)
- RNTX 33.6K
- KORE 16.0K
- Earning Date
- RNTX 08-13-2025
- KORE 08-14-2025
- Dividend Yield
- RNTX N/A
- KORE N/A
- EPS Growth
- RNTX N/A
- KORE N/A
- EPS
- RNTX N/A
- KORE N/A
- Revenue
- RNTX N/A
- KORE $282,254,000.00
- Revenue This Year
- RNTX N/A
- KORE $4.66
- Revenue Next Year
- RNTX N/A
- KORE $6.71
- P/E Ratio
- RNTX N/A
- KORE N/A
- Revenue Growth
- RNTX N/A
- KORE N/A
- 52 Week Low
- RNTX $1.35
- KORE $1.10
- 52 Week High
- RNTX $4.40
- KORE $4.88
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- KORE 44.65
- Support Level
- RNTX N/A
- KORE $2.22
- Resistance Level
- RNTX N/A
- KORE $2.49
- Average True Range (ATR)
- RNTX 0.00
- KORE 0.19
- MACD
- RNTX 0.00
- KORE -0.02
- Stochastic Oscillator
- RNTX 0.00
- KORE 12.13
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.